These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28196905)

  • 1. A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
    Ryu MH; Ryoo BY; Kim TW; Kim SB; Lim HS; Bae KS; Park SR; Jo YW; Cho HJ; Kang YK
    Oncologist; 2017 Feb; 22(2):129-e8. PubMed ID: 28196905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
    Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
    Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
    Hong YS; Kim KP; Lim HS; Bae KS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim H; Kim TW
    Invest New Drugs; 2013 Jun; 31(3):616-22. PubMed ID: 22695940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation.
    Lim HS; Bae KS; Jung JA; Noh YH; Hwang AK; Jo YW; Hong YS; Kim K; Lee JL; Park SJ; Kim JE; Kang YK; Kim TW
    Clin Ther; 2015 Feb; 37(2):402-17. PubMed ID: 25579984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
    Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
    Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.
    Lee KW; Lee KH; Zang DY; Park YI; Shin DB; Kim JW; Im SA; Koh SA; Yu KS; Cho JY; Jung JA; Bang YJ
    Oncologist; 2015 Aug; 20(8):896-7. PubMed ID: 26112004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
    Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
    Am J Clin Oncol; 2001 Aug; 24(4):404-7. PubMed ID: 11474274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
    Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
    Matsuda G; Kunisaki C; Makino H; Fukahori M; Kimura J; Sato T; Oshima T; Nagano Y; Fuii S; Takagawa R; Kosaka T; Ono HA; Akiyama H; Ichikawa Y
    Anticancer Res; 2009 Jul; 29(7):2863-7. PubMed ID: 19596975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
    Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
    Kurzrock R; Gabrail N; Chandhasin C; Moulder S; Smith C; Brenner A; Sankhala K; Mita A; Elian K; Bouchard D; Sarantopoulos J
    Mol Cancer Ther; 2012 Feb; 11(2):308-16. PubMed ID: 22203732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study).
    Kim SB; Seo JH; Ahn JH; Kim TY; Kang SY; Sohn J; Yang Y; Park KH; Moon YW; Lim S; Kang MJ; Yoon KE; Cho HJ; Lee KS
    Ther Adv Med Oncol; 2021; 13():17588359211061989. PubMed ID: 34925553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.